<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960646</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0738</org_study_id>
    <secondary_id>NCI-2016-01915</secondary_id>
    <secondary_id>2014-0738</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02960646</nct_id>
  </id_info>
  <brief_title>Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies the side effects of engineered donor stem cell transplant in
      treating patients with hematologic malignancies. Sometimes the transplanted cells from a
      donor can make an immune response against the body's normal cells (called graft-versus-host
      disease). Using T cells specially selected from donor blood in the laboratory for transplant
      may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety of a modified peripheral blood (PB) graft for haploidentical
      transplantation, obtained by using depletion of naive, cluster of differentiation (CD)45RA+ T
      cells.

      SECONDARY OBJECTIVES:

      I. To estimate the proportion of patients with engraftment/graft failure. II. To determine
      the day 100 and 6 month non-relapse mortality (NRM). III. To estimate the cumulative
      incidence of grade 2-4 and 3-4 acute graft versus (vs.) host disease (aGVHD).

      IV. To assess the rate of chronic GVHD within the first year post transplantation.

      V. To assess immune reconstitution and the incidence of infectious episodes. VI. To assess
      disease response, disease-free survival (DFS) and overall survival (OS) after
      transplantation.

      VII. To compare results with a retrospective cohort of patients treated with bone marrow
      graft on protocol 2009-0266.

      OUTLINE:

      Patients receive melphalan intravenously (IV) over 30 minutes on day -6 and fludarabine
      phosphate IV over 1 hour on days -6 to -3. Patients undergo total-body irradiation (TBI) on
      day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also
      receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive
      tacrolimus IV for 2 weeks and orally (PO) for at least 4 months. Beginning on day 7, patients
      receive filgrastim subcutaneously (SC) daily. Patients with CD20 positive lymphoma may
      receive rituximab IV on days -13, -6, 1, and 8.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment failure defined as primary graft failure, grade 3-4 acute graft versus host disease (aGVHD), or non-relapse mortality</measure>
    <time_frame>Up to 100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized by number of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious episodes</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized by number of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) time</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) time</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Complete Remission</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Blasts Under 10 Percent of Bone Marrow Nucleated Cells</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Minimal Residual Disease</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Recurrent Chronic Lymphocytic Leukemia</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Therapy-Related Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo total-body irradiation (TBI) on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>FILGRASTIM, LICENSE HOLDER UNSPECIFIED</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo CD45RA depleted peripheral blood stem cell transplantation</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (peripheral blood stem cell transplantation)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lack of a human leukocyte antigen (HLA) matched related donor, lack of an immediately
             available 8/8 HLA matched unrelated donor

          -  Patients must be diagnosed with a high-risk and/or advanced hematologic malignancy
             defined as one of the following

          -  Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high-risk features
             including adverse cytogenetic such as t(9;22), t(1;19), t(4;11), or MLL gene
             rearrangements; in second or greater morphologic remission; persistent minimal
             residual disease

          -  Acute myeloid leukemia (AML) in CR1 with intermediate-risk disease and persistent
             detectable minimal residual disease (MRD), or with high-risk features defined as:
             greater than 1 cycle of induction therapy required to achieve remission; preceding
             myelodysplastic syndrome (MDS) or myeloproliferative disease; presence of FLT3
             mutations or internal tandem duplications, DNMT3a, TET2, MLL-partial tandem
             duplication (PTD), ASXL1, PHF6; FAB M6 or M7 classification; adverse cytogenetics
             including: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17,
             +8, complex (&gt; 3 abnormalities)

          -  Patients with AML must have less than 10% bone marrow blasts and &lt; 100/mcL absolute
             peripheral blood blast count

          -  Patients with AML in CR2, subsequent CR or with active disease at transplant (&lt; 10%
             bone marrow blasts)

          -  MDS with International Prognostic Scoring System (IPSS) intermediate-2 or higher,
             therapy-related MDS or chronic myelomonocytic leukemia (CMML)

          -  Aplastic anemia with absolute neutrophil count (ANC) &lt; 1,000 and transfusion dependent
             after failed immunosuppression therapy

          -  Chronic myeloid leukemia (CML) &gt;= 1st chronic phase, after failed &gt;=2 lines of
             tyrosine kinase inhibitors; patients who progressed to blast phase must be in
             morphologic remission at transplant

          -  Relapsed Hodgkin's disease or non-Hodgkin's lymphoma (NHL)

          -  Patients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic
             lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens
             with &lt; 25% involvement by CLL/SLL cells

          -  Patients with lymphoblastic lymphoma in remission or after partial response to
             chemotherapy

          -  Patients with poor prognosis multiple myeloma by cytogenetics del13, del 17p, t(4;14)
             or t(14;16) or hypodiploidy, with advanced disease (stage &gt;= 2) and /or relapsed after
             autologous stem cell transplant

          -  Zubrod performance status 0-1 or Karnofsky performance status &gt; 70%; patients &gt; 50
             years will have to have a Sorror Comorbidity Index =&lt; 3

          -  Available haploidentical donor willing and eligible to undergo a peripheral blood
             collection

          -  Left ventricular ejection fraction (LVEF) &gt; 40%

          -  Bilirubin =&lt; 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) =&lt; 200 IU/ml for adults; conjugated (direct)
             bilirubin &lt; 2 x upper limit of normal

          -  Serum creatinine clearance &gt;= 50 ml/min (calculated with Cockcroft-Gault formula)

          -  Diffusing capacity for carbon monoxide (DLCO) &gt;= 45% predicted corrected for
             hemoglobin

          -  Patient or patient's legal representative must provide written informed consent

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) positive; active hepatitis B or C

          -  Patients with active infections; the principal investigator (PI) is the final arbiter
             of the eligibility

          -  Liver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis

          -  Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2
             months

          -  History of another primary malignancy that has not been in remission for at least 3
             years; (the following are exempt from the 3-year limit: nonmelanoma skin cancer, fully
             excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and
             cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP
             smear)

          -  Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization

          -  Inability to comply with medical therapy or follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan O Ciurea</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Ciurea</last_name>
    <phone>713-792-8750</phone>
    <email>sciurea@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan O. Ciurea</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Stefan O. Ciurea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

